Year: 2018

PvP Biologics Announces First-in-Human Clinical Trials for a Novel Therapeutic for Celiac Disease

September 6, 2018

SAN DIEGO and SEATTLE, September 6, 2018 – PvP Biologics, Inc. (“PvP”) today announced the initiation of two first-in-human clinical trials for Kuma062, a product candidate for the treatment of celiac disease. Kuma062 is a uniquely engineered, recombinant enzyme that is active under acidic stomach conditions and has high specificity for the parts of gluten…

Read More